Report Library
All Reports
IN VIVO Article: Up-Front Deal Value Doesn't Reflect Peak Commercial Potential
September 10, 2015
BioMedTracker is featuring content from respected outside sources to augment its original report content. This article was
originally published by IN VIVO, September 2015. IN VIVO is the premier strategic business resource for the biopharma, medtech, and
diagnostics industries.
For more information about IN VIVO, please visit IN VIVO here.
There's no correlation between the up-front payment made in the deal and the peak sales for the drug that was the product of the deal. Second in a series of follow-ups to IN VIVO's 2014 study comparing/contrasting likelihood of approval and up-front payments on alliances, and the outcomes of relevant deals.
For the full report, please download the PDF version at the top of this page.
For our disclosures, please read the BioMedTracker Research Standards.
For more information about IN VIVO, please visit IN VIVO here.
There's no correlation between the up-front payment made in the deal and the peak sales for the drug that was the product of the deal. Second in a series of follow-ups to IN VIVO's 2014 study comparing/contrasting likelihood of approval and up-front payments on alliances, and the outcomes of relevant deals.
For the full report, please download the PDF version at the top of this page.
For our disclosures, please read the BioMedTracker Research Standards.
| Disease Group Covered: |
Cardiovascular
Infectious Disease Metabolic Neurology Oncology Psychiatry Respiratory |
| Indications Covered: |
Castleman's Disease
Guillain-Barré Syndrome |
Additional Resources: